Crispr Therapeutics AG Cash Flow Reinvestment Rate
Crispr Therapeutics AG cash flow reinvestment rate. Crispr Therapeutics AG (CRSP) has a Cash Flow Reinvestment Rate of 0.90x as of March 2024, reinvesting $98.52 Million (capex $721.00K plus investments $-97.80 Million) from operating cash flow of $109.75 Million. Explore Crispr Therapeutics AG cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Crispr Therapeutics AG (2015–2021)
Cash flow reinvestment rate of Crispr Therapeutics AG from 2015 to 2021. Historical reinvestment intensity for Crispr Therapeutics AG across 3 annual periods. Explore CRSP capex reinvestment rate to see what proportion of operating cash flow is directed to capital expenditures.
Crispr Therapeutics AG Cash Flow Reinvestment Rate by Year (2015–2021)
Crispr Therapeutics AG cash flow reinvestment rate by year from 2015 to 2021. Year-by-year capital reinvestment analysis for Crispr Therapeutics AG. For the full cash flow conversion analysis, see how efficiently does Crispr Therapeutics AG generate cash.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 1.92x | $1.04 Billion | $538.97 Million | $81.70 Million | ▲ +1259.5% |
| 2019 | 0.14x | $8.01 Million | $56.68 Million | $6.68 Million | ▲ +569.7% |
| 2015 | 0.02x | $1.25 Million | $59.43 Million | $1.15 Million | — |